Assessing systemic sclerosis (SSc) disease activity is challenging, and improved outcome measures are needed. This Review describes clinical and biochemical outcome measures of distinct features of SSc, with an emphasis on the dermatological manifestations and interstitial lung disease, including insights into biomarkers gained from single-cell RNA sequencing.

This Evidence-Based Guideline presents the latest treatment recommendations for medication selection in psoriatic arthritis (PsA), covering the six clinical domains of PsA, related conditions and associated comorbidities, and reflecting important advances in the field since the previous update.

Individuals with chronic diseases that require constant medical support are particularly vulnerable during wartime and often remain so after the last shot has been fired. What consequences might the Russia–Ukraine war bring for rheumatology?

New research attempts to explore the cause of plasmacytoid dendritic cell hyperactivation in systemic lupus erythematosus by focusing on genetic risk variation.

The findings of a new study suggest that the adipokine FABP4 promotes multiple pathological changes in rheumatoid arthritis and could represent a new therapeutic target.

Three new reports of results from two clinical trials of bimekizumab indicate that it is safe and efficacious for the long-term treatment of patients with ankylosing spondylitis or psoriatic arthritis.

A new study uncovers a protective role for epidermal S100A9 in psoriasis and psoriatic arthritis, and highlights this alarmin as a potential biomarker of disease progression.

New research shows that annexin A1 has a protective role in periprosthetic osteolysis and could offer a therapeutic approach to this common cause of arthroplasty failure.

New research shows that one of the two main isoforms of the human FOXP3 transcription factor is associated with inflammatory transcriptional regulation and autoimmunity.